GSK's pullback from cell therapy continues as Immatics allia...

Immatics has become the latest partner for GSK in the area of cell therapy for cancer to see its alliance shelved, just two and a half years after being set up.

GSK begins cancer cell therapy tie-up with Immatics

Cancer biotech Immatics has begun a collaboration with GlaxoSmithKline to develop novel therapies built around its T-cell-based technology.

Celgene strikes $1.5bn cell therapy deal with Immatics

European biotech round-up: Ablynx’s big break and more

This week has seen another flurry of activity in European biotech, with a mixture of encouraging clinical trials and new funding lifting the sector.

Amgen, Immatics strike $1bn cancer R&D deal

Amgen and German biotech company Immatics have struck a deal potentially worth more than $1 billion, focused on a new generation of bispecific antibody cancer therapies.